Health · Pharma & Biotech · 5 hrs ago
J&J tests once-daily prostate cancer drug candidate
Johnson & Johnson is testing a prostate cancer drug candidate called JNJ-6143.
The medicine is designed as a once-daily pill.
The trial is aimed at patients whose cancer continued to progress after several treatments.
Prostate cancer is described as the second most common cancer in men after lung cancer.
The trial is testing whether the experimental drug could help this group of patients.
The clinical trial is ongoing, and no results are given.
Johnson & Johnson is conducting clinical trials of JNJ-6143, a once-daily drug candidate for prostate cancer.
The drug is intended for patients whose cancer continues to progress despite receiving several treatments.
The report identifies Johnson & Johnson as a US pharmaceutical company.
- Who
- Johnson & Johnson is conducting the trial.
- What
- It is testing JNJ-6143, a once-daily prostate cancer drug candidate.
- When
- The article was published on October 30, 2026; the trial timing is not stated.
- Where
- Not stated.
- Why
- The candidate is aimed at patients whose cancer continues to progress despite several treatments.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug candidate
- JNJ-6143
- Dosing
- Once daily
- Company
- Johnson & Johnson
- Article publication
- October 30, 2026